Progenics Pharmaceuticals Inc., of New York, said results of a phase II study of 1404, a PSMA-targeted small-molecule SPECT/CT imaging agent designed to visualize prostate cancer, published in the Journal of Nuclear Medicine, demonstrated the sensitivity of 1404 to detect prostate cancer using both visual and semiquantitative tumor to background (TBR) scores.